Journal Article
. 2014 Dec; 33(9):983-91.
doi: 10.1200/JCO.2014.58.1967.

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers

Carsten Denkert 1 Gunter von Minckwitz 2 Jan C Brase 2 Bruno V Sinn 2 Stephan Gade 2 Ralf Kronenwett 2 Berit M Pfitzner 2 Christoph Salat 2 Sherene Loi 2 Wolfgang D Schmitt 2 Christian Schem 2 Karin Fisch 2 Silvia Darb-Esfahani 2 Keyur Mehta 2 Christos Sotiriou 2 Stephan Wienert 2 Peter Klare 2 Fabrice André 2 Frederick Klauschen 2 Jens-Uwe Blohmer 2 Kristin Krappmann 2 Marcus Schmidt 2 Hans Tesch 2 Sherko Kümmel 2 Peter Sinn 2 Christian Jackisch 2 Manfred Dietel 2 Toralf Reimer 2 Michael Untch 2 Sibylle Loibl 2 
  • PMID: 25534375
  •     364 citations


Purpose: Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) -positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial.

Patients And Methods: GeparSixto investigated the effect of adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response (pCR). A total of 580 tumors were evaluated before random assignment for stromal TILs and lymphocyte-predominant BC (LPBC). mRNA expression of immune-activating (CXCL9, CCL5, CD8A, CD80, CXCL13, IGKC, CD21) as well as immunosuppressive factors (IDO1, PD-1, PD-L1, CTLA4, FOXP3) was measured in 481 tumors.

Results: Increased levels of stromal TILs predicted pCR in univariable (P < .001) and multivariable analyses (P < .001). pCR rate was 59.9% in LPBC and 33.8% for non-LPBC (P < .001). pCR rates ≥ 75% were observed in patients with LPBC tumors treated with PMCb, with a significant test for interaction with therapy in the complete (P = .002) and HER2-positive (P = .006), but not the TNBC, cohorts. Hierarchic clustering of mRNA markers revealed three immune subtypes with different pCR rates (P < .001). All 12 immune mRNA markers were predictive for increased pCR. The highest odds ratios (ORs) were observed for PD-L1 (OR, 1.57; 95% CI, 1.34 to 1.86; P < .001) and CCL5 (OR, 1.41; 95% CI, 1.23 to 1.62; P < .001).

Conclusion: Immunologic factors were highly significant predictors of therapy response in the GeparSixto trial, particularly in patients treated with Cb. After further standardization, they could be included in histopathologic assessment of BC.

Breast Cancer Update 2014 - Focus on the Patient and the Tumour.
N Maass, F Schütz, +7 authors, M P Lux.
Geburtshilfe Frauenheilkd, 2015 Mar 24; 75(2). PMID: 25797960    Free PMC article.
Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer.
Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano.
Ecancermedicalscience, 2015 May 02; 9. PMID: 25932042    Free PMC article.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
François Bertucci, Pascal Finetti, +6 authors, Steven van Laere.
Oncotarget, 2015 May 06; 6(15). PMID: 25940795    Free PMC article.
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Fanny Le Du, Bedrich L Eckhardt, +5 authors, Naoto T Ueno.
Oncotarget, 2015 May 15; 6(15). PMID: 25973541    Free PMC article.
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).
M Untch, N Harbeck, +22 authors, S Loibl.
Geburtshilfe Frauenheilkd, 2015 Jul 15; 75(6). PMID: 26166836    Free PMC article.
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Roberto Salgado, Carsten Denkert, +13 authors, Sherene Loi.
JAMA Oncol, 2015 Jul 17; 1(4). PMID: 26181252    Free PMC article.
Highly Cited.
Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.
Aliyah M Weinstein, Walter J Storkus.
Adv Cancer Res, 2015 Jul 29; 128. PMID: 26216634    Free PMC article.
Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration.
Hirva Mamdani, Shadia I Jalal, Nasser Hanna.
Curr Treat Options Oncol, 2015 Aug 04; 16(10). PMID: 26233240
Clinical implications of molecular heterogeneity in triple negative breast cancer.
Brian D Lehmann, Jennifer A Pietenpol.
Breast, 2015 Aug 09; 24 Suppl 2. PMID: 26253813    Free PMC article.
The Right Treatment for the Right Patient - Personalised Treatment of Breast Cancer.
A Scharl, T Kühn, T Papathemelis, A Salterberg.
Geburtshilfe Frauenheilkd, 2015 Aug 11; 75(7). PMID: 26257405    Free PMC article.
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer.
Sung Gwe Ahn, Joon Jeong, SoonWon Hong, Woo Hee Jung.
J Pathol Transl Med, 2015 Aug 19; 49(5). PMID: 26278518    Free PMC article.
Relevance of tumor-infiltrating lymphocytes in breast cancer.
Sathana Dushyanthen, Paul A Beavis, +5 authors, Sherene Loi.
BMC Med, 2015 Aug 25; 13. PMID: 26300242    Free PMC article.
Highly Cited. Review.
Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
Joseph Obeid, Yinin Hu, Craig L Slingluff.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320060    Free PMC article.
Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State.
Constantin N Baxevanis, Sonia A Perez.
Vaccines (Basel), 2015 Sep 10; 3(3). PMID: 26350597    Free PMC article.
CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.
Lisa A Carey.
Clin Cancer Res, 2015 Sep 17; 21(18). PMID: 26374072    Free PMC article.
The in vitro immunogenic potential of caspase-3 proficient breast cancer cells with basal low immunogenicity is increased by hypofractionated irradiation.
Bernhard Kötter, Benjamin Frey, +5 authors, Udo S Gaipl.
Radiat Oncol, 2015 Sep 19; 10. PMID: 26383236    Free PMC article.
Quantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancer.
Hong-Mei Zheng, Chuang Chen, +5 authors, Sheng-Rong Sun.
Tumour Biol, 2015 Sep 20; 37(2). PMID: 26385773
Triple negative breast cancer: looking for the missing link between biology and treatments.
Giuseppe Palma, Giuseppe Frasci, +7 authors, Massimiliano D'Aiuto.
Oncotarget, 2015 Sep 21; 6(29). PMID: 26387133    Free PMC article.
Highly Cited. Review.
An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer.
Carlo C Maley, Konrad Koelble, +2 authors, Yinyin Yuan.
Breast Cancer Res, 2015 Sep 24; 17(1). PMID: 26395345    Free PMC article.
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
Leticia De Mattos-Arruda, Giulia Bottai, +11 authors, Libero Santarpia.
Oncotarget, 2015 Oct 10; 6(35). PMID: 26452030    Free PMC article.
Highly Cited.
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Edith A Perez, Karla V Ballman, +4 authors, Frederick L Baehner.
JAMA Oncol, 2015 Oct 16; 2(1). PMID: 26469139    Free PMC article.
Highly Cited.
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.
Vassiliki Kotoula, Kyriakos Chatzopoulos, +18 authors, George Fountzilas.
Oncotarget, 2015 Oct 28; 7(4). PMID: 26506242    Free PMC article.
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Patrick N Harter, Simon Bernatz, +17 authors, Michel Mittelbronn.
Oncotarget, 2015 Oct 31; 6(38). PMID: 26517811    Free PMC article.
Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis.
Haruo Ohtani, Kazuko Mori-Shiraishi, Morio Nakajima, Hamaichi Ueki.
Pathol Int, 2015 Nov 05; 65(12). PMID: 26530981    Free PMC article.
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.
Christian Jackisch, Nadia Harbeck, +22 authors, Michael Untch.
Breast Care (Basel), 2015 Nov 12; 10(3). PMID: 26557827    Free PMC article.
Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery.
Agnieszka Kolacinska, Barbara Cebula-Obrzut, +7 authors, Piotr Smolewski.
Oncol Lett, 2015 Dec 02; 10(2). PMID: 26622629    Free PMC article.
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Silvia Darb-Esfahani, Catarina Alisa Kunze, +9 authors, Korinna Jöhrens.
Oncotarget, 2015 Dec 02; 7(2). PMID: 26625204    Free PMC article.
Highly Cited.
Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Peter Savas, Roberto Salgado, +4 authors, Sherene Loi.
Nat Rev Clin Oncol, 2015 Dec 17; 13(4). PMID: 26667975
Highly Cited. Review.
A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model.
Hatem Soliman, Melanie Mediavilla-Varela, Scott J Antonia.
Breast Cancer (Dove Med Press), 2016 Jan 01; 7. PMID: 26719725    Free PMC article.
Managing breast cancer in younger women: challenges and solutions.
Foluso O Ademuyiwa, Amy Cyr, Jennifer Ivanovich, Maria A Thomas.
Breast Cancer (Dove Med Press), 2016 Jan 06; 8. PMID: 26730210    Free PMC article.
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
David H Munn, Andrew L Mellor.
Trends Immunol, 2016 Feb 04; 37(3). PMID: 26839260    Free PMC article.
Highly Cited. Review.
The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.
Samuel A Funt, Paul B Chapman.
Clin Cancer Res, 2016 Feb 05; 22(10). PMID: 26842238    Free PMC article.
Biomarkers of residual disease after neoadjuvant therapy for breast cancer.
Frederique Penault-Llorca, Nina Radosevic-Robin.
Nat Rev Clin Oncol, 2016 Feb 10; 13(8). PMID: 26856744
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Luisa Carbognin, Sara Pilotto, +6 authors, Giampaolo Tortora.
Oncologist, 2016 Feb 13; 21(3). PMID: 26865589    Free PMC article.
Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.
Nghia Nguyen, Emily Bellile, +15 authors, Head and Neck SPORE Program Investigators.
Head Neck, 2016 Feb 18; 38(7). PMID: 26879675    Free PMC article.
Highly Cited.
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
H Raza Ali, Aliakbar Dariush, +16 authors, Carlos Caldas.
Breast Cancer Res, 2016 Feb 18; 18(1). PMID: 26882907    Free PMC article.
Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
Brian Z Ring, David R Hout, +6 authors, Robert S Seitz.
BMC Cancer, 2016 Feb 26; 16. PMID: 26908167    Free PMC article.
Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.
H Bonsang-Kitzis, B Sadacca, +4 authors, F Reyal.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942074    Free PMC article.
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.
Kosuke Kawaguchi, Eiji Suzuki, +3 authors, Masakazu Toi.
Breast Cancer, 2016 Mar 05; 24(1). PMID: 26942414    Free PMC article.
Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?
Abigail T Berman, Charles B Simone.
Transl Lung Cancer Res, 2016 Mar 10; 5(1). PMID: 26958509    Free PMC article.
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Patrizia Vici, Cristiana Ercolani, +12 authors, Marcello Maugeri-Saccà.
J Exp Clin Cancer Res, 2016 Apr 04; 35. PMID: 27039292    Free PMC article.
Neoadjuvant nab-paclitaxel in the treatment of breast cancer.
Naoto T Ueno, Eleftherios P Mamounas.
Breast Cancer Res Treat, 2016 Apr 14; 156(3). PMID: 27072366    Free PMC article.
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
Paula García-Teijido, María Luque Cabal, Ignacio Peláez Fernández, Yolanda Fernández Pérez.
Clin Med Insights Oncol, 2016 Apr 16; 10(Suppl 1). PMID: 27081325    Free PMC article.
Highly Cited. Review.
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
Alexander S Brodsky, Jinjun Xiong, +6 authors, Yihong Wang.
BMC Cancer, 2016 Apr 20; 16. PMID: 27090210    Free PMC article.
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
Renata Duchnowska, Rafał Pęksa, +13 authors, Polish Brain Metastasis Consortium.
Breast Cancer Res, 2016 Apr 28; 18(1). PMID: 27117582    Free PMC article.
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
Laura Rosa Brunet, Thorsten Hagemann, +2 authors, Aurelien Marabelle.
Oncoimmunology, 2016 May 04; 5(4). PMID: 27141395    Free PMC article.
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2016 Oct 19; 13(11). PMID: 27184417    Free PMC article.
Highly Cited. Review.
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.
Lance D Miller, Jeff A Chou, +13 authors, Francesco M Marincola.
Cancer Immunol Res, 2016 May 20; 4(7). PMID: 27197066    Free PMC article.
Immunological Mechanisms in Breast Cancer - from Bench to Bedside.
Carsten Denkert, Florian Schütz.
Breast Care (Basel), 2016 May 31; 11(2). PMID: 27239169    Free PMC article.
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer.
Barbara Ingold Heppner, Sibylle Loibl, Carsten Denkert.
Breast Care (Basel), 2016 May 31; 11(2). PMID: 27239170    Free PMC article.
Checkpoint Inhibitors and Their Application in Breast Cancer.
Davide Bedognetti, Cristina Maccalli, +2 authors, Barbara Seliger.
Breast Care (Basel), 2016 May 31; 11(2). PMID: 27239172    Free PMC article.
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Akira I Hida, Yasuaki Sagara, +8 authors, Yasuyo Ohi.
Breast Cancer Res Treat, 2016 Jun 05; 158(1). PMID: 27260189    Free PMC article.
Triple-negative breast cancer: treatment challenges and solutions.
Joëlle Collignon, Laurence Lousberg, Hélène Schroeder, Guy Jerusalem.
Breast Cancer (Dove Med Press), 2016 Jun 11; 8. PMID: 27284266    Free PMC article.
Highly Cited.
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, +6 authors, Jennifer A Pietenpol.
PLoS One, 2016 Jun 17; 11(6). PMID: 27310713    Free PMC article.
Highly Cited.
Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.
Ke Wang, Jianjun Xu, Tao Zhang, Dan Xue.
Oncotarget, 2016 Jun 23; 7(28). PMID: 27329588    Free PMC article.
The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
Daniel G Stover, Jonathan L Coloff, +3 authors, Laura M Selfors.
Clin Cancer Res, 2016 Jun 23; 22(24). PMID: 27330058    Free PMC article.
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.
Carsten Denkert, Stephan Wienert, +41 authors, Roberto Salgado.
Mod Pathol, 2016 Jul 02; 29(10). PMID: 27363491
Highly Cited.
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.
A Musolino, N Naldi, +14 authors, V Guarneri.
Pharmacogenomics J, 2016 Jul 06; 16(5). PMID: 27378608
Spatial Heterogeneity in the Tumor Microenvironment.
Yinyin Yuan.
Cold Spring Harb Perspect Med, 2016 Aug 03; 6(8). PMID: 27481837    Free PMC article.
Towards tumor immunodiagnostics.
Helen Kourea, Vassiliki Kotoula.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563650    Free PMC article.
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Silvia Darb-Esfahani, Carsten Denkert, +20 authors, Sibylle Loibl.
Oncotarget, 2016 Sep 10; 7(42). PMID: 27611952    Free PMC article.
Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes.
Vassiliki Kotoula, Sotiris Lakis, +18 authors, George Fountzilas.
PLoS One, 2016 Sep 30; 11(9). PMID: 27685159    Free PMC article.
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
Rin Ogiya, Naoki Niikura, +13 authors, Yutaka Tokuda.
Cancer Sci, 2016 Oct 12; 107(12). PMID: 27727484    Free PMC article.
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
Rico D Bense, Christos Sotiriou, +5 authors, Rudolf S N Fehrmann.
J Natl Cancer Inst, 2016 Oct 16; 109(1). PMID: 27737921    Free PMC article.
Highly Cited.
Novel therapeutic strategies for patients with triple-negative breast cancer.
Jun-Fei Zhang, Jia Liu, Yu Wang, Bin Zhang.
Onco Targets Ther, 2016 Nov 02; 9. PMID: 27799799    Free PMC article.
Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score.
Adnan Mujahid Khan, Yinyin Yuan.
Sci Rep, 2016 Nov 05; 6. PMID: 27812028    Free PMC article.
The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.
Michaela Semeraro, Julien Adam, +15 authors, Guido Kroemer.
Oncoimmunology, 2016 Nov 18; 5(10). PMID: 27853639    Free PMC article.
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Giulia Bottai, Carlotta Raschioni, +10 authors, Libero Santarpia.
Breast Cancer Res, 2016 Dec 04; 18(1). PMID: 27912781    Free PMC article.
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.
H Raza Ali, Leon Chlon, +2 authors, Carlos Caldas.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959923    Free PMC article.
Highly Cited.
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Stephen J Luen, Roberto Salgado, +8 authors, Sherene Loi.
Lancet Oncol, 2016 Dec 15; 18(1). PMID: 27964843    Free PMC article.
Highly Cited.
Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses.
Yoshihiro Komohara, Koji Ohnishi, Motohiro Takeya.
Cancer Sci, 2016 Dec 22; 108(3). PMID: 28002629    Free PMC article.
A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.
Anne-Sophie Hamy, Hélène Bonsang-Kitzis, +7 authors, Fabien Reyal.
PLoS One, 2016 Dec 23; 11(12). PMID: 28005906    Free PMC article.
Claudin-Low Breast Cancer; Clinical & Pathological Characteristics.
Kay Dias, Anna Dvorkin-Gheva, +6 authors, Anita L Bane.
PLoS One, 2017 Jan 04; 12(1). PMID: 28045912    Free PMC article.
Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.
Richard Greil, Evelyn Hutterer, Tanja Nicole Hartmann, Lisa Pleyer.
Cell Commun Signal, 2017 Jan 20; 15(1). PMID: 28100240    Free PMC article.
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Hitomi Mori, Makoto Kubo, +10 authors, Masafumi Nakamura.
Oncotarget, 2017 Jan 21; 8(9). PMID: 28107186    Free PMC article.
Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy.
Thaer Khoury, Vidya Nagrale, +3 authors, Song Yao.
Appl Immunohistochem Mol Morphol, 2017 Feb 12; 26(8). PMID: 28187033    Free PMC article.
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
Laurence Buisseret, Soizic Garaud, +14 authors, Karen Willard-Gallo.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197375    Free PMC article.
Highly Cited.
Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.
Marta Usó, Eloísa Jantus-Lewintre, +6 authors, Rafael Sirera.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197383    Free PMC article.
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
Andreas D Hartkopf, Florin-Andrei Taran, +4 authors, Sara Y Brucker.
Breast Care (Basel), 2017 Feb 24; 11(6). PMID: 28228704    Free PMC article.
Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Anne-Sophie Heimes, K Madjar, +9 authors, M Schmidt.
J Cancer Res Clin Oncol, 2017 Mar 03; 143(7). PMID: 28251349
Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Satish K Noonepalle, Franklin Gu, +22 authors, Huidong Shi.
Cancer Immunol Res, 2017 Mar 08; 5(4). PMID: 28264810    Free PMC article.
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Bojana Jovanović, Ingrid A Mayer, +21 authors, Jennifer A Pietenpol.
Clin Cancer Res, 2017 Mar 09; 23(15). PMID: 28270498    Free PMC article.
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.
Wouter Hendrickx, Ines Simeone, +14 authors, Davide Bedognetti.
Oncoimmunology, 2017 Mar 28; 6(2). PMID: 28344865    Free PMC article.
Highly Cited.
Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer.
Silvia C Formenti, Encouse B Golden, +6 authors, Yelena Novik.
Oncoimmunology, 2017 Apr 14; 6(3). PMID: 28405497    Free PMC article.
Is tumor cellularity in primary invasive breast carcinoma of prognostic significance?
Emily S Reisenbichler, William Dupont, W Dale Plummer, Omar Hameed.
Virchows Arch, 2017 Apr 20; 470(6). PMID: 28421340
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
Juan Jin, Wenwen Zhang, +2 authors, Xiaoxiang Guan.
Cancer Biol Ther, 2017 May 12; 18(6). PMID: 28494179    Free PMC article.
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Gautier Stoll, Yuting Ma, +3 authors, Guido Kroemer.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507808    Free PMC article.
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Sacha Gnjatic, Vincenzo Bronte, +13 authors, Lisa H Butterfield.
J Immunother Cancer, 2017 May 19; 5. PMID: 28515944    Free PMC article.
Highly Cited. Review.
Advancing Immunotherapy in Metastatic Breast Cancer.
Mariam Mansour, Zhi Ling Teo, Stephen J Luen, Sherene Loi.
Curr Treat Options Oncol, 2017 May 24; 18(6). PMID: 28534250
Immunotherapy for Breast Cancer: What Are We Missing?
Robert H Vonderheide, Susan M Domchek, Amy S Clark.
Clin Cancer Res, 2017 Jun 03; 23(11). PMID: 28572258    Free PMC article.
Highly Cited.
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.
Emma Nolan, Peter Savas, +13 authors, Geoffrey J Lindeman.
Sci Transl Med, 2017 Jun 09; 9(393). PMID: 28592566    Free PMC article.
Highly Cited.
Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells.
Holger Bronger, Anne Karge, +5 authors, Manfred Schmitt.
Oncol Lett, 2017 Jun 11; 13(6). PMID: 28599423    Free PMC article.
Precision medicine in breast cancer: reality or utopia?
Ali Bettaieb, Catherine Paul, +3 authors, François Ghiringhelli.
J Transl Med, 2017 Jun 19; 15(1). PMID: 28623955    Free PMC article.
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Jamunarani Veeraraghavan, Carmine De Angelis, +5 authors, Rachel Schiff.
Breast, 2017 Jul 09; 34 Suppl 1. PMID: 28687441    Free PMC article.
Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Xia Liu, Julia Y S Tsang, +5 authors, Gary M Tse.
Oncologist, 2017 Jul 14; 22(11). PMID: 28701569    Free PMC article.
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.
Tristan A Barnes, Eitan Amir.
Br J Cancer, 2017 Jul 14; 117(4). PMID: 28704840    Free PMC article.
Highly Cited. Review.
DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.
Jana Jeschke, Martin Bizet, +12 authors, François Fuks.
J Clin Invest, 2017 Jul 18; 127(8). PMID: 28714863    Free PMC article.
Novel therapeutic strategies in the treatment of triple-negative breast cancer.
Karima Oualla, Heba M El-Zawahry, +7 authors, Tamer M Fouad.
Ther Adv Med Oncol, 2017 Jul 19; 9(7). PMID: 28717401    Free PMC article.
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
Nadine Tung, Judy E Garber, +8 authors, Stuart J Schnitt.
NPJ Breast Cancer, 2016 Feb 24; 2. PMID: 28721372    Free PMC article.
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
Timothy R Wilson, Jianjun Yu, +17 authors, Mark R Lackner.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721382    Free PMC article.
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
Fresia Pareja, Felipe C Geyer, +3 authors, Jorge S Reis-Filho.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721389    Free PMC article.
Highly Cited. Review.
The immune contexture in cancer prognosis and treatment.
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer.
Nat Rev Clin Oncol, 2017 Jul 26; 14(12). PMID: 28741618
Highly Cited. Review.
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Shuzhen Liu, Bingshu Chen, +8 authors, Torsten O Nielsen.
JAMA Oncol, 2017 Jul 28; 3(11). PMID: 28750133    Free PMC article.
Neopterin as a biomarker of immune response in cancer patients.
Bohuslav Melichar, Martina Spisarová, +3 authors, Hana Študentová.
Ann Transl Med, 2017 Aug 02; 5(13). PMID: 28758106    Free PMC article.
HER2-positive breast cancer is lost in translation: time for patient-centered research.
Isabelle Gingras, Géraldine Gebhart, Evandro de Azambuja, Martine Piccart-Gebhart.
Nat Rev Clin Oncol, 2017 Aug 02; 14(11). PMID: 28762384
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
Shona Hendry, Roberto Salgado, +97 authors, Stephen B Fox.
Adv Anat Pathol, 2017 Aug 05; 24(5). PMID: 28777142    Free PMC article.
Highly Cited. Review.
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Vasiliki Pelekanou, Daniel E Carvajal-Hausdorf, +7 authors, David L Rimm.
Breast Cancer Res, 2017 Aug 09; 19(1). PMID: 28784153    Free PMC article.
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
Lironne Wein, Peter Savas, +3 authors, Sherene Loi.
Front Oncol, 2017 Aug 22; 7. PMID: 28824872    Free PMC article.
Correlation between Tumor-Infiltrating Lymphocytes and Pathological Response in Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy in H. Adam Malik General Hospital.
Kamal Basri Siregar, Jamaluddin Pane, Rikson Siburian.
Case Rep Oncol, 2017 Sep 08; 10(2). PMID: 28878653    Free PMC article.
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Gloria Romagnoli, Meike Wiedermann, +6 authors, Ibrahim Alkatout.
Int J Mol Sci, 2017 Sep 09; 18(9). PMID: 28885584    Free PMC article.
Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Carmen Herrero-Vicent, Angel Guerrero, +7 authors, Amparo Ruiz-Simón.
Ecancermedicalscience, 2017 Sep 14; 11. PMID: 28900472    Free PMC article.
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
Reza Nejati, Jennifer B Goldstein, +13 authors, Huamin Wang.
Pancreas, 2017 Sep 14; 46(9). PMID: 28902789    Free PMC article.
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Sibylle Loibl, Lorena de la Pena, +17 authors, Sherene Loi.
Eur J Cancer, 2017 Sep 20; 85. PMID: 28923573    Free PMC article.
Predictors of responses to immune checkpoint blockade in advanced melanoma.
N Jacquelot, M P Roberti, +47 authors, L Zitvogel.
Nat Commun, 2017 Sep 21; 8(1). PMID: 28928380    Free PMC article.
Highly Cited.
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.
Sathana Dushyanthen, Zhi Ling Teo, +15 authors, Sherene Loi.
Nat Commun, 2017 Sep 21; 8(1). PMID: 28928458    Free PMC article.
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Sasagu Kurozumi, Takaaki Fujii, +4 authors, Hiroyuki Kuwano.
Med Mol Morphol, 2017 Sep 25; 50(4). PMID: 28936553
Infiltration of γ⁢δ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer.
Roni Allaoui, Catharina Hagerling, +3 authors, Karin Leandersson.
Cancer Biomark, 2017 Oct 25; 20(4). PMID: 29060923    Free PMC article.
Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
Fangyuan Shao, Heng Sun, Chu-Xia Deng.
Oncotarget, 2017 Oct 27; 8(42). PMID: 29069872    Free PMC article.
Role of Platinum in Early-Stage Triple-Negative Breast Cancer.
Alyssa La Belle, Jude Khatib, William P Schiemann, Shaveta Vinayak.
Curr Treat Options Oncol, 2017 Nov 08; 18(11). PMID: 29110096
T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire.
John F Beausang, Amanda J Wheeler, +4 authors, Stephen R Quake.
Proc Natl Acad Sci U S A, 2017 Nov 16; 114(48). PMID: 29138313    Free PMC article.
The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review.
Tao Xu, Bang-Shun He, +7 authors, Shu-Kui Wang.
J Cancer, 2017 Nov 21; 8(18). PMID: 29151971    Free PMC article.
Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy.
Jacques Raphael, S Nofech-Mozes, +2 authors, S Gandhi.
Pathol Oncol Res, 2017 Dec 10; 25(4). PMID: 29222623
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Takahiro Maeda, Masayuki Hiraki, +10 authors, Donald Kufe.
Cancer Res, 2017 Dec 22; 78(1). PMID: 29263152    Free PMC article.
Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab.
Tiia J Honkanen, Tiina Moilanen, +5 authors, Jussi P Koivunen.
Sci Rep, 2017 Dec 23; 7(1). PMID: 29269742    Free PMC article.
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
Yuka Asano, Shinichiro Kashiwagi, +11 authors, Masaichi Ohira.
BMC Cancer, 2017 Dec 29; 17(1). PMID: 29282021    Free PMC article.
Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.
Naveen K R Chalakur-Ramireddy, Suresh B Pakala.
Biosci Rep, 2018 Jan 05; 38(1). PMID: 29298879    Free PMC article.
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.
Diwakar Davar, Nathan Bahary.
Target Oncol, 2018 Jan 06; 13(2). PMID: 29302770
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Hua Zheng, Masha Zeltsman, +3 authors, Prasad S Adusumilli.
Immunotherapy, 2018 Jan 18; 9(11). PMID: 29338609    Free PMC article.
Immune gene expression and response to chemotherapy in advanced breast cancer.
Theodoros Foukakis, John Lövrot, +14 authors, Thomas Hatschek.
Br J Cancer, 2018 Jan 26; 118(4). PMID: 29370583    Free PMC article.
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Bruna Cerbelli, Angelina Pernazza, +10 authors, Leopoldo Costarelli.
Biomed Res Int, 2018 Feb 02; 2017. PMID: 29387716    Free PMC article.
T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.
Jiemiao Hu, Chuang Sun, +4 authors, Shulin Li.
Clin Cancer Res, 2018 Feb 03; 24(12). PMID: 29391351    Free PMC article.
Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers.
Anita Grigoriadis, Patrycja Gazinska, +9 authors, Sarah E Pinder.
J Pathol Clin Res, 2018 Feb 09; 4(1). PMID: 29416876    Free PMC article.
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.
Amanda J Oliver, Peter K H Lau, +4 authors, Clare Y Slaney.
Front Immunol, 2018 Feb 16; 9. PMID: 29445373    Free PMC article.
The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.
Gero Brockhoff, Stephan Seitz, +4 authors, Anja Kathrin Wege.
Oncotarget, 2018 Feb 22; 9(5). PMID: 29464065    Free PMC article.
Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
Marcus Schmidt, Veronika Weyer-Elberich, +12 authors, Heikki Joensuu.
Breast Cancer Res, 2018 Feb 28; 20(1). PMID: 29482642    Free PMC article.
The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Yanchun Li, Mateusz Opyrchal, +4 authors, Thaer Khoury.
Breast Cancer Res Treat, 2018 Mar 11; 170(2). PMID: 29524062    Free PMC article.
Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer.
Jhajaira M Araujo, Andrea C Gomez, +9 authors, Joseph A Pinto.
Sci Rep, 2018 Mar 22; 8(1). PMID: 29559701    Free PMC article.
Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
Sung Gwe Ahn, Yoon Jin Cha, +3 authors, Joon Jeong.
BMC Cancer, 2018 Mar 27; 18(1). PMID: 29573739    Free PMC article.
The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis.
Xuan Li, Danian Dai, +3 authors, Weidong Wei.
J Cancer, 2018 Mar 28; 9(5). PMID: 29581764    Free PMC article.
Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Gabriel von Waldenfels, Sibylle Loibl, +11 authors, Jens-Uwe Blohmer.
Oncotarget, 2018 Apr 11; 9(20). PMID: 29632634    Free PMC article.
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.
Erika J Crosby, Junping Wei, +10 authors, Zachary C Hartman.
Oncoimmunology, 2018 May 04; 7(5). PMID: 29721371    Free PMC article.
Mechanisms of immune evasion in breast cancer.
Joshua P Bates, Roshanak Derakhshandeh, Laundette Jones, Tonya J Webb.
BMC Cancer, 2018 May 13; 18(1). PMID: 29751789    Free PMC article.
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
Ji Hyun Park, Jin-Hee Ahn, Sung-Bae Kim.
ESMO Open, 2018 May 17; 3(Suppl 1). PMID: 29765774    Free PMC article.
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Claudio Vernieri, Alessia Mennitto, +12 authors, Filippo de Braud.
Sci Rep, 2018 Jun 09; 8(1). PMID: 29880896    Free PMC article.
Breast Cancer Immunotherapy: An Update.
Issam Makhoul, Mohammad Atiq, Ahmed Alwbari, Thomas Kieber-Emmons.
Breast Cancer (Auckl), 2018 Jun 15; 12. PMID: 29899661    Free PMC article.
High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
Joe Yeong, Jeffrey Chun Tatt Lim, +10 authors, Jabed Iqbal.
Front Immunol, 2018 Jun 15; 9. PMID: 29899747    Free PMC article.
Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis.
Kyu Sang Lee, Bo Hyung Kim, +4 authors, Eun Shin.
Cancer Sci, 2018 Jun 28; 109(9). PMID: 29949671    Free PMC article.
The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.
André Steven, Barbara Seliger.
Breast Care (Basel), 2018 Jun 29; 13(1). PMID: 29950962    Free PMC article.
Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer.
Yunxuan Wang, Tieying Dong, +3 authors, Qingyuan Zhang.
J Breast Cancer, 2018 Jul 03; 21(2). PMID: 29963107    Free PMC article.
Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer.
Andrea Zapater-Moros, Angelo Gámez-Pozo, +9 authors, Juan Ángel Fresno Vara.
Oncotarget, 2018 Jul 03; 9(45). PMID: 29963222    Free PMC article.
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.
Lorenzo Pilla, Cristina Maccalli.
Biomedicines, 2018 Jul 14; 6(3). PMID: 30004433    Free PMC article.
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Maki Tanioka, Cheng Fan, +18 authors, Charles M Perou.
Clin Cancer Res, 2018 Jul 25; 24(21). PMID: 30037817    Free PMC article.
Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Anthony Cheung, James Opzoomer, +26 authors, Sophia N Karagiannis.
Clin Cancer Res, 2018 Aug 03; 24(20). PMID: 30068707    Free PMC article.
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
Anna Diana, Elisena Franzese, +8 authors, Michele Orditura.
Curr Oncol Rep, 2018 Aug 22; 20(10). PMID: 30128845
Systematic Review.
Is there a role for immunotherapy in HER2-positive breast cancer?
Esther Holgado, Jose Perez-Garcia, Maria Gion, Javier Cortes.
NPJ Breast Cancer, 2018 Aug 23; 4. PMID: 30131972    Free PMC article.
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
Miao Ruan, Tian Tian, +4 authors, Ruohong Shui.
Diagn Pathol, 2018 Sep 02; 13(1). PMID: 30170605    Free PMC article.
Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
Jia Wu, Xuejie Li, +4 authors, Ruijiang Li.
Breast Cancer Res, 2018 Sep 05; 20(1). PMID: 30176944    Free PMC article.
Current concepts and future directions in neoadjuvant chemotherapy of breast cancer.
Rupert Bartsch, Elisabeth Bergen, Arik Galid.
Memo, 2018 Sep 18; 11(3). PMID: 30220926    Free PMC article.
Distribution and prognostic value of tumor‑infiltrating T cells in breast cancer.
Shaoda Meng, Li Li, +3 authors, Kunxian Yang.
Mol Med Rep, 2018 Sep 18; 18(5). PMID: 30221739    Free PMC article.
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.
Alexios Matikas, John Lövrot, +9 authors, Theodoros Foukakis.
Oncoimmunology, 2018 Sep 20; 7(9). PMID: 30228933    Free PMC article.
Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy.
Wataru Goto, Shinichiro Kashiwagi, +9 authors, Masaichi Ohira.
ESMO Open, 2018 Sep 21; 3(6). PMID: 30233820    Free PMC article.
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Estefanía Paula Juliá, Analía Amante, +2 authors, Estrella Mariel Levy.
Front Immunol, 2018 Oct 09; 9. PMID: 30294328    Free PMC article.
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Xu Liang, Adrien Briaux, +12 authors, Céline Callens.
J Hematol Oncol, 2018 Oct 12; 11(1). PMID: 30305115    Free PMC article.
Immunogenic effects of chemotherapy-induced tumor cell death.
Yi-Jun Wang, Rochelle Fletcher, Jian Yu, Lin Zhang.
Genes Dis, 2018 Oct 16; 5(3). PMID: 30320184    Free PMC article.
Highly Cited. Review.
[Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis].
C Denkert, S Loibl, +2 authors, F Klauschen.
Pathologe, 2018 Oct 18; 39(6). PMID: 30327858
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
Paul Gass, Michael P Lux, +12 authors, Marius Wunderle.
BMC Cancer, 2018 Oct 31; 18(1). PMID: 30373556    Free PMC article.
Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy.
Wataru Goto, Shinichiro Kashiwagi, +7 authors, Masaichi Ohira.
J Transl Med, 2018 Nov 11; 16(1). PMID: 30413161    Free PMC article.
Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer.
Javier Cuello-López, Ana Fidalgo-Zapata, Laura López-Agudelo, Elsa Vásquez-Trespalacios.
PLoS One, 2018 Nov 15; 13(11). PMID: 30427884    Free PMC article.
Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer.
Wataru Goto, Shinichiro Kashiwagi, +8 authors, Masaichi Ohira.
BMC Cancer, 2018 Nov 21; 18(1). PMID: 30453914    Free PMC article.
Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer.
Koji Takada, Shinichiro Kashiwagi, +7 authors, Masaichi Ohira.
J Transl Med, 2018 Nov 21; 16(1). PMID: 30454008    Free PMC article.
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Jianqin Lu, Xiangsheng Liu, +6 authors, Andre E Nel.
ACS Nano, 2018 Nov 30; 12(11). PMID: 30481959    Free PMC article.
Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study.
Jiahui Huang, Xiaosong Chen, +7 authors, Kunwei Shen.
Cancer Res Treat, 2019 Feb 13; 51(4). PMID: 30744321    Free PMC article.
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Stephen Chia, Phillipe L Bedard, +8 authors, Lesley Seymour.
Oncologist, 2019 Aug 20; 24(11). PMID: 31420468    Free PMC article.
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value.
Federica Miglietta, Gaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci.
Oncologist, 2019 Aug 25; 24(11). PMID: 31444294    Free PMC article.
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer.
H Vihervuori, T A Autere, +5 authors, P Kronqvist.
J Cancer Res Clin Oncol, 2019 Sep 29; 145(12). PMID: 31562550    Free PMC article.
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.
A T J Lee, W Chew, +9 authors, P H Huang.
Sci Rep, 2019 Oct 12; 9(1). PMID: 31601875    Free PMC article.
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
Amanda Fitzpatrick, Andrew Tutt.
Ther Adv Med Oncol, 2019 Nov 09; 11. PMID: 31700549    Free PMC article.
Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes.
Alex Mremi, Gloria Broadwater, +5 authors, Allison Hall.
PLoS One, 2019 Nov 09; 14(11). PMID: 31703083    Free PMC article.
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Jin Sun Lee, Susan E Yost, +14 authors, Yuan Yuan.
Breast Cancer Res, 2019 Nov 11; 21(1). PMID: 31703728    Free PMC article.
Histological tumor response assessment in colorectal liver metastases after neoadjuvant chemotherapy: impact of the variation in tumor regression grading and peritumoral lymphocytic infiltration.
Yibo Cai, Xingang Lu, +3 authors, Wei Wu.
J Cancer, 2019 Nov 19; 10(23). PMID: 31737121    Free PMC article.
Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer.
Shi-Chao Zhang, Zu-Quan Hu, +6 authors, Zhu Zeng.
J Cancer, 2019 Nov 26; 10(24). PMID: 31762828    Free PMC article.
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors.
Holger Bronger, Viktor Magdolen, Peter Goettig, Tobias Dreyer.
Cancer Metastasis Rev, 2019 Sep 05; 38(3). PMID: 31482487    Free PMC article.
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
Bruno Valentin Sinn, Karsten E Weber, +15 authors, Sibylle Loibl.
Breast Cancer Res, 2019 Dec 13; 21(1). PMID: 31829264    Free PMC article.
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy.
Xinyan Li, Mozhi Wang, +6 authors, Yingying Xu.
J Breast Cancer, 2020 Jan 04; 22(4). PMID: 31897326    Free PMC article.
Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy.
Sha Zhou, Lei Zhao, +6 authors, Mian Xi.
Cancers (Basel), 2019 Feb 06; 11(2). PMID: 30717285    Free PMC article.
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review.
B Pellegrino, A Musolino, +6 authors, C Solinas.
Transl Oncol, 2020 Jan 07; 13(2). PMID: 31901781    Free PMC article.
The therapeutic potential of targeting tryptophan catabolism in cancer.
Christiane A Opitz, Luis F Somarribas Patterson, +4 authors, Saskia Trump.
Br J Cancer, 2019 Dec 11; 122(1). PMID: 31819194    Free PMC article.
Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Maria Lucia Hirata Katayama, René Aloísio da Costa Vieira, +11 authors, Maria Aparecida Azevedo Koike Folgueira.
Cells, 2019 Dec 11; 8(12). PMID: 31817155    Free PMC article.
A Review of the Potential Role of Human Cytomegalovirus (HCMV) Infections in Breast Cancer Carcinogenesis and Abnormal Immunity.
Jürgen Geisler, Joel Touma, +2 authors, Katja Vetvik.
Cancers (Basel), 2019 Nov 27; 11(12). PMID: 31766600    Free PMC article.
Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer.
Anne-Sophie Hamy, Lisa Derosa, +18 authors, Fabien Reyal.
Oncoimmunology, 2020 Feb 01; 9(1). PMID: 32002287    Free PMC article.
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
Carmine De Angelis, Chandandeep Nagi, +22 authors, Rachel Schiff.
Clin Cancer Res, 2019 Oct 28; 26(3). PMID: 31653641    Free PMC article.
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Sherene Loi, Damien Drubay, +19 authors, Stefan Michiels.
J Clin Oncol, 2019 Jan 17; 37(7). PMID: 30650045    Free PMC article.
Highly Cited.
Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer.
Wenhui Li, Ming Xu, +7 authors, Pengfei Yi.
J Transl Med, 2020 Feb 20; 18(1). PMID: 32070368    Free PMC article.
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.
Carlo Fremd, Mario Hlevnjak, +13 authors, Andreas Schneeweiss.
Breast Care (Basel), 2019 Apr 26; 14(1). PMID: 31019444    Free PMC article.
Prognostic Value of Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma.
Matthew E Spector, Emily Bellile, +10 authors, University of Michigan Head and Neck SPORE Program.
JAMA Otolaryngol Head Neck Surg, 2019 Sep 06; 145(11). PMID: 31486841    Free PMC article.
Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
Sasagu Kurozumi, Kenichi Inoue, +5 authors, Ken Shirabe.
Sci Rep, 2019 Feb 09; 9(1). PMID: 30733496    Free PMC article.
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Andreas Heindl, Ivana Sestak, +3 authors, Yinyin Yuan.
J Natl Cancer Inst, 2017 Sep 02; 110(2). PMID: 28859291    Free PMC article.
Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
Anosheh Afghahi, Natasha Purington, +15 authors, Allison W Kurian.
Clin Cancer Res, 2018 Mar 28; 24(12). PMID: 29581131    Free PMC article.
Checkpoint blockade in the treatment of breast cancer: current status and future directions.
Lironne Wein, Stephen J Luen, +2 authors, Sherene Loi.
Br J Cancer, 2018 May 29; 119(1). PMID: 29808015    Free PMC article.
A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.
Lisa I Greene, Tullia C Bruno, +6 authors, Jennifer K Richer.
Mol Cancer Res, 2018 Aug 26; 17(1). PMID: 30143553    Free PMC article.
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A Emens, Cristina Cruz, +16 authors, Peter Schmid.
JAMA Oncol, 2018 Sep 23; 5(1). PMID: 30242306    Free PMC article.
Highly Cited.
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Sylvia Adams, Jennifer R Diamond, +9 authors, John Powderly.
JAMA Oncol, 2018 Oct 23; 5(3). PMID: 30347025    Free PMC article.
Highly Cited.
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Xia Yang, Jia Rao, Wentao Yang, Ruohong Shui.
Target Oncol, 2018 Nov 09; 13(6). PMID: 30406444    Free PMC article.
Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3.
Mayassa J Bou-Dargham, Yuhang Liu, Qing-Xiang Amy Sang, Jinfeng Zhang.
PLoS One, 2018 Dec 05; 13(12). PMID: 30513096    Free PMC article.
CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Vasiliki Pelekanou, Franz Villarroel-Espindola, +2 authors, David L Rimm.
Breast Cancer Res, 2018 Dec 19; 20(1). PMID: 30558648    Free PMC article.
Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer.
Koji Takada, Shinichiro Kashiwagi, +7 authors, Masaichi Ohira.
J Transl Med, 2019 Jan 09; 17(1). PMID: 30616624    Free PMC article.
Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer.
Jian Yang, Junnan Xu, Ying E, Tao Sun.
Cancer Med, 2019 Jan 12; 8(2). PMID: 30632318    Free PMC article.
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
Mayanne M T Zhu, Amanda R Dancsok, Torsten O Nielsen.
Curr Oncol Rep, 2019 Jan 20; 21(1). PMID: 30659394
Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.
Kang Wang, Hai-Lin Li, +5 authors, Hong-Yuan Li.
Cancer Med, 2019 Jan 25; 8(2). PMID: 30677255    Free PMC article.
Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
Joe Yeong, Jeffrey Chun Tatt Lim, +15 authors, Puay Hoon Tan.
J Immunother Cancer, 2019 Feb 08; 7(1). PMID: 30728081    Free PMC article.
Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer.
Dachuan Zhang, Wenting He, +6 authors, Jingting Jiang.
Front Immunol, 2019 Feb 15; 10. PMID: 30761139    Free PMC article.
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.
Rim S Kim, Nan Song, +18 authors, Katherine L Pogue-Geile.
J Natl Cancer Inst, 2019 Mar 20; 111(8). PMID: 30888406    Free PMC article.
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.
Gaia Griguolo, Tomás Pascual, +2 authors, Aleix Prat.
J Immunother Cancer, 2019 Mar 30; 7(1). PMID: 30922362    Free PMC article.
Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
Chao Liu, Qinyong Hu, +5 authors, Jinming Yu.
J Transl Med, 2019 Apr 12; 17(1). PMID: 30971280    Free PMC article.
Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node.
Kim M van Pul, Ronald J C L M Vuylsteke, +5 authors, Tanja D de Gruijl.
J Immunother Cancer, 2019 May 24; 7(1). PMID: 31118093    Free PMC article.
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Bradley A Hancock, Yu-Hsiang Chen, +14 authors, Milan Radovich.
Breast Cancer Res, 2019 Aug 07; 21(1). PMID: 31383035    Free PMC article.
Platinum Derivatives Effects on Anticancer Immune Response.
Cédric Rébé, Lucie Demontoux, Thomas Pilot, François Ghiringhelli.
Biomolecules, 2019 Dec 22; 10(1). PMID: 31861811    Free PMC article.
Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer.
Filiz Çelebi, Filiz Agacayak, +11 authors, Vahit Özmen.
Eur Radiol, 2019 Dec 12; 30(4). PMID: 31822972
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Guoxuan Gao, Zihan Wang, Xiang Qu, Zhongtao Zhang.
BMC Cancer, 2020 Mar 07; 20(1). PMID: 32131780    Free PMC article.
Systematic Review.
Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Yu-Ge Bai, Guo-Xuan Gao, +4 authors, Ling Xu.
Chin Med J (Engl), 2020 Feb 12; 133(5). PMID: 32044815    Free PMC article.
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Adrienne G Waks, Daniel G Stover, +26 authors, Sara M Tolaney.
Clin Cancer Res, 2019 May 08; 25(15). PMID: 31061067    Free PMC article.
Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment.
Russell K Pachynski, Ping Wang, +10 authors, Brian A Zabel.
Front Immunol, 2019 May 30; 10. PMID: 31139180    Free PMC article.
Incorporating biomarkers to improve statistical power of immunotherapeutic neoadjuvant clinical trials in patients with triple-negative breast cancer.
Feng Gao, Guoqiao Wang, +3 authors, Chengjie Xiong.
Stat Biopharm Res, 2019 Aug 31; 11(3). PMID: 31467642    Free PMC article.
Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1.
Jing Zhao, Jian Huang.
Chin Med J (Engl), 2020 Feb 28; 133(7). PMID: 32106121    Free PMC article.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.
Ioannis Zerdes, Emmanouil G Sifakis, +6 authors, Theodoros Foukakis.
Mol Oncol, 2020 Mar 03; 14(5). PMID: 32115850    Free PMC article.
[Immunoncology and tumor infiltrating lymphocytes-new strategies for therapy and diagnosis of breast cancer].
Carsten Denkert.
Pathologe, 2020 Apr 05; 41(3). PMID: 32246201
Comprehensive Analysis of the Expression and Prognosis for TDO2 in Breast Cancer.
Qiang Liu, Jie Zhai, +4 authors, Jing Wang.
Mol Ther Oncolytics, 2020 Apr 30; 17. PMID: 32346606    Free PMC article.
Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem.
Jacob M Smigiel, Sarah E Taylor, +3 authors, Mark W Jackson.
J Cancer Metastasis Treat, 2019 Jan 01; 5. PMID: 32355893    Free PMC article.
Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer.
Shiyuan Wang, Yakun Wang, +8 authors, Lei Yang.
J Cell Mol Med, 2020 Apr 07; 24(10). PMID: 32249526    Free PMC article.
The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Michael S Toss, Asima Abidi, +8 authors, Emad A Rakha.
Br J Cancer, 2020 Mar 24; 122(10). PMID: 32203210    Free PMC article.
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
Zuzana Kos, Elvire Roblin, +91 authors, International Immuno-Oncology Biomarker Working Group.
NPJ Breast Cancer, 2020 May 16; 6. PMID: 32411819    Free PMC article.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.
Francesco Schettini, Tomás Pascual, +25 authors, Aleix Prat.
Cancer Treat Rev, 2020 Jan 31; 84. PMID: 32000054    Free PMC article.
Systematic Review.
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Signe Korsgaard Skriver, Maj-Britt Jensen, +2 authors, Anne-Vibeke Laenkholm.
Breast Cancer Res, 2020 May 16; 22(1). PMID: 32410705    Free PMC article.
Profiles of immune infiltration and its relevance to survival outcome in meningiomas.
Xiaodong Chen, Fen Tian, Peng Lun, Yugong Feng.
Biosci Rep, 2020 May 08; 40(5). PMID: 32378707    Free PMC article.
The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.
Laura Annaratone, Eliano Cascardi, +5 authors, Caterina Marchiò.
Pathobiology, 2020 Apr 24; 87(2). PMID: 32325459    Free PMC article.
Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data.
Zixiao Lu, Siwen Xu, +5 authors, Kun Huang.
JCO Clin Cancer Inform, 2020 May 27; 4. PMID: 32453636    Free PMC article.
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
Markus Eckstein, Pamela Strissel, +21 authors, BRIDGE Consortium e.V., Mannheim, Germany.
J Immunother Cancer, 2020 May 26; 8(1). PMID: 32448798    Free PMC article.
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Jieqiong Liu, Qiang Liu, +10 authors, Erwei Song.
J Immunother Cancer, 2020 May 26; 8(1). PMID: 32448804    Free PMC article.
Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies.
Terisse A Brocato, Ursa Brown-Glaberman, +10 authors, Vittorio Cristini.
JCI Insight, 2019 Mar 06; 5. PMID: 30835256    Free PMC article.
Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women.
Yara Abdou, Kristopher Attwood, +9 authors, Angela R Omilian.
Breast Cancer Res, 2020 Jun 11; 22(1). PMID: 32517730    Free PMC article.
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Jörg Hänze, Moritz Wegner, +2 authors, Axel Hegele.
Target Oncol, 2020 Jun 05; 15(3). PMID: 32495158    Free PMC article.
Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-positive, HER2-negative Breast Cancer Patients.
Claudia Mazo, Stephen Barron, Catherine Mooney, William M Gallagher.
Cancers (Basel), 2020 May 07; 12(5). PMID: 32369904    Free PMC article.
Triple negative breast cancer: special histological types and emerging therapeutic methods.
Lu Cao, Yun Niu.
Cancer Biol Med, 2020 Jun 27; 17(2). PMID: 32587770    Free PMC article.
Influences of preoperative metformin on immunological factors in early breast cancer.
Takahiro Tsukioki, Tadahiko Shien, +10 authors, Shinichi Toyooka.
Cancer Chemother Pharmacol, 2020 Jun 14; 86(1). PMID: 32533334    Free PMC article.
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
Jin Sun Lee, Susan E Yost, Yuan Yuan.
Cancers (Basel), 2020 Jun 04; 12(6). PMID: 32486021    Free PMC article.
Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor-infiltrating lymphocytes.
Yuka Asano, Shinichiro Kashiwagi, +8 authors, Masaichi Ohira.
Mol Clin Oncol, 2020 Jul 28; 13(2). PMID: 32714546    Free PMC article.
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Sanxing Guo, Sibylle Loibl, +3 authors, Carsten Denkert.
Cancer Res Treat, 2020 Feb 06; 52(3). PMID: 32019278    Free PMC article.
Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor-mutated lung adenocarcinoma.
Chi-Cheng Li, Chih-Bin Lin, +5 authors, Yi-Feng Wu.
Medicine (Baltimore), 2020 Jul 25; 99(29). PMID: 32702917    Free PMC article.
Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features.
Mercedes Herrera Juarez, Pablo Tolosa Ortega, Ana Sanchez de Torre, Eva Ciruelos Gil.
Breast Care (Basel), 2020 Aug 11; 15(3). PMID: 32774214    Free PMC article.
Optimal Systemic Treatment for Early Triple-Negative Breast Cancer.
Jenny Furlanetto, Sibylle Loibl.
Breast Care (Basel), 2020 Aug 11; 15(3). PMID: 32774215    Free PMC article.
Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer.
Estefanía Paula Juliá, José Mordoh, Estrella Mariel Levy.
Cells, 2020 Jul 02; 9(7). PMID: 32605193    Free PMC article.
[Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?]
Marcus Schmidt.
J Gynakol Endokrinol, 2020 Aug 25;. PMID: 32837693    Free PMC article.
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
Paola De Cicco, Giuseppe Ercolano, Angela Ianaro.
Front Immunol, 2020 Aug 28; 11. PMID: 32849585    Free PMC article.
Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
Tess O'Meara, Michal Marczyk, +6 authors, Lajos Pusztai.
JCO Precis Oncol, 2020 Sep 15; 4. PMID: 32923897    Free PMC article.
Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis.
Lin He, Yaling Wang, +5 authors, Yong Huang.
BMC Womens Health, 2020 Sep 07; 20(1). PMID: 32891135    Free PMC article.
Circulating microRNAs and their role in the immune response in triple-negative breast cancer.
Patricia Piña-Sánchez, Hilda-Alicia Valdez-Salazar, Martha-Eugenia Ruiz-Tachiquín.
Oncol Lett, 2020 Sep 25; 20(5). PMID: 32968446    Free PMC article.
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ.
Alberto Farolfi, Elisabetta Petracci, +11 authors, Andrea Rocca.
Front Oncol, 2020 Sep 26; 10. PMID: 32974178    Free PMC article.
Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
Vasiliki Pelekanou, William E Barlow, +12 authors, Lajos Pusztai.
Mol Cancer Ther, 2018 Mar 29; 17(6). PMID: 29588392    Free PMC article.
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.
Pelagia G Tsoutsou, Khalil Zaman, +3 authors, Marie-Catherine Vozenin.
Front Oncol, 2019 Jan 09; 8. PMID: 30619749    Free PMC article.
Association of markers of systemic and local inflammation with prognosis of patients with rectal cancer who received neoadjuvant radiotherapy.
Xueqing Zhang, Jinluan Li, +7 authors, Junxin Wu.
Cancer Manag Res, 2019 Jan 15; 11. PMID: 30636893    Free PMC article.
Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.
Yuichiro Miyoshi, Tadahiko Shien, +14 authors, Hiroko Yamashita.
Oncol Lett, 2019 Jan 25; 17(2). PMID: 30675282    Free PMC article.
Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis.
Sasagu Kurozumi, Hiroshi Matsumoto, +6 authors, Hiroyuki Kuwano.
Oncol Lett, 2019 Mar 15; 17(3). PMID: 30867728    Free PMC article.
Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity.
Ishita Gupta, Rasha M Sareyeldin, +4 authors, Ala-Eddin Al Moustafa.
Cancers (Basel), 2019 Mar 16; 11(3). PMID: 30871273    Free PMC article.
Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma.
Chungsu Hwang, So Jung Lee, +4 authors, Kyung Un Choi.
Oncol Lett, 2019 Apr 05; 17(5). PMID: 30944645    Free PMC article.
Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment.
Robert A Belderbos, Joachim G J V Aerts, Heleen Vroman.
Mol Ther Oncolytics, 2019 Apr 26; 13. PMID: 31020037    Free PMC article.
Immunotherapy in breast cancer.
Soley Bayraktar, Sameer Batoo, Scott Okuno, Stefan Glück.
J Carcinog, 2019 Jun 05; 18. PMID: 31160888    Free PMC article.
Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
Lianzhou Yang, Rujun Xue, Chunhua Pan.
Onco Targets Ther, 2019 Jun 14; 12. PMID: 31190869    Free PMC article.
Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial.
Susanne Crocamo, Renata Binato, +11 authors, Eliana Abdelhay.
Ther Adv Med Oncol, 2019 Jun 19; 11. PMID: 31210800    Free PMC article.
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.
Gabrielle Planes-Laine, Philippe Rochigneux, +4 authors, Anthony Gonçalves.
Cancers (Basel), 2019 Jul 25; 11(7). PMID: 31336685    Free PMC article.
Highly Cited. Review.
A Regulatory Science Initiative to Harmonize and Standardize Digital Pathology and Machine Learning Processes to Speed up Clinical Innovation to Patients.
Hetal Desai Marble, Richard Huang, +14 authors, Jochen K Lennerz.
J Pathol Inform, 2020 Oct 13; 11. PMID: 33042601    Free PMC article.
CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Masanori Oshi, Mariko Asaoka, +5 authors, Kazuaki Takabe.
Int J Mol Sci, 2020 Sep 26; 21(18). PMID: 32971948    Free PMC article.
Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway.
Kim M van Pul, Ronald J C L M Vuylsteke, +4 authors, Tanja D de Gruijl.
J Immunother Cancer, 2020 Oct 14; 8(2). PMID: 33046620    Free PMC article.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gagan K Gupta, Amber L Collier, +13 authors, Amy H Tang.
Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32846967    Free PMC article.
Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC.
Luca Campedel, Paul Blanc-Durand, +15 authors, Sylvie Giacchetti.
Cancers (Basel), 2020 Sep 23; 12(9). PMID: 32957722    Free PMC article.
Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes.
Anne-Sophie Heimes, Franziska Härtner, +10 authors, Marcus Schmidt.
Int J Mol Sci, 2020 Oct 03; 21(19). PMID: 33003293    Free PMC article.
Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Masanori Oshi, Mariko Asaoka, +7 authors, Kazuaki Takabe.
Cancers (Basel), 2020 Oct 23; 12(10). PMID: 33086518    Free PMC article.
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Margaret L Axelrod, Mellissa J Nixon, +23 authors, Justin M Balko.
Clin Cancer Res, 2020 Aug 23; 26(21). PMID: 32826327    Free PMC article.
VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.
Takaaki Fujii, Tomoko Hirakata, +6 authors, Ken Shirabe.
In Vivo, 2020 Sep 03; 34(5). PMID: 32871794    Free PMC article.
An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
Silei Sui, Xin An, +13 authors, Man Li.
Theranostics, 2020 Nov 19; 10(26). PMID: 33204321    Free PMC article.
Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice.
Agnese Losurdo, Rita De Sanctis, +9 authors, Armando Santoro.
Sci Rep, 2020 Nov 20; 10(1). PMID: 33208857    Free PMC article.
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Sara A Hurvitz, Jennifer L Caswell-Jin, +22 authors, Dennis J Slamon.
Nat Commun, 2020 Nov 19; 11(1). PMID: 33203854    Free PMC article.
Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype.
Andrea Angius, Paolo Cossu-Rocca, +7 authors, Maria Rosaria De Miglio.
Cancers (Basel), 2020 Nov 12; 12(11). PMID: 33171872    Free PMC article.
Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.
Eirini Thanopoulou, Leila Khader, +5 authors, Valentina Guarneri.
Cancers (Basel), 2020 Nov 14; 12(11). PMID: 33182657    Free PMC article.
Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic.
Ernesto Rojas-Jiménez, Javier César Mejía-Gómez, +18 authors, Felipe Vaca-Paniagua.
Genes (Basel), 2020 Nov 25; 11(11). PMID: 33227964    Free PMC article.
Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Zhao-Hua Gao, Cun-Xin Li, Ming Liu, Jia-Yuan Jiang.
BMC Cancer, 2020 Nov 27; 20(1). PMID: 33238978    Free PMC article.
Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes.
Elaine M Walsh, Maccon M Keane, +2 authors, Sharon A Glynn.
Crit Rev Oncog, 2016 Jan 01; 21(5-6). PMID: 29431082    Free PMC article.
New horizons in breast cancer: the promise of immunotherapy.
L de la Cruz-Merino, N Palazón-Carrión, +6 authors, GEICAM (Spanish Breast Cancer Research Group) and GÉTICA (Spanish Group for Cancer Immuno-Biotherapy).
Clin Transl Oncol, 2018 Jun 20; 21(2). PMID: 29916188
Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment.
Koji Takada, Shinichiro Kashiwagi, +9 authors, Masaichi Ohira.
Br J Cancer, 2018 Jul 24; 119(5). PMID: 30033444    Free PMC article.
Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
Lisa König, Fabian D Mairinger, +5 authors, Agnes Bankfalvi.
BMC Cancer, 2019 Feb 06; 19(1). PMID: 30717704    Free PMC article.
Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy.
Yi-Feng Wu, Sung-Chao Chu, +2 authors, Tso-Fu Wang.
Biomed Res Int, 2019 Mar 06; 2019. PMID: 30834254    Free PMC article.
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer.
Di Maria Jiang, Anthony Fyles, +6 authors, Srikala S Sridhar.
Oncotarget, 2019 May 21; 10(31). PMID: 31105877    Free PMC article.
Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC.
Qianqian Zhao, Gang Chen, +4 authors, Jian He.
Radiat Oncol, 2019 May 28; 14(1). PMID: 31133034    Free PMC article.
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
Andreas Schneeweiss, Carsten Denkert, +5 authors, Hans-Joachim Lück.
Geburtshilfe Frauenheilkd, 2019 Jun 21; 79(6). PMID: 31217629    Free PMC article.
Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer.
Koji Takada, Shinichiro Kashiwagi, +7 authors, Masaichi Ohira.
BMC Cancer, 2019 Jun 27; 19(1). PMID: 31234828    Free PMC article.
The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment.
Avital Vorontsova, Tal Kan, Ziv Raviv, Yuval Shaked.
J Clin Med, 2020 Dec 06; 9(12). PMID: 33276524    Free PMC article.
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Christine Lundgren, Pär-Ola Bendahl, +6 authors, Lisa Rydén.
Breast Cancer Res, 2020 Dec 29; 22(1). PMID: 33357231    Free PMC article.
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.
Hsing-Ju Wu, Pei-Yi Chu.
Int J Mol Sci, 2021 Jan 14; 22(2). PMID: 33435254    Free PMC article.
The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy.
Davide Bedognetti, Jessica Roelands, +2 authors, Wouter Hendrickx.
Emerg Top Life Sci, 2017 Dec 12; 1(5). PMID: 33525803    Free PMC article.

;. PMID: 33574291
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Priyanka Sharma, Bruce F Kimler, +35 authors, Qamar Khan.
Clin Cancer Res, 2020 Nov 20; 27(4). PMID: 33208340    Free PMC article.
Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy.
Houshi Xu, Qingwei Zhu, +4 authors, Meiqing Lou.
Cancer Cell Int, 2021 Feb 14; 21(1). PMID: 33579299    Free PMC article.
Update on systemic treatment in early triple negative breast cancer.
Martín Núñez Abad, Silvia Calabuig-Fariñas, +6 authors, Carlos Camps Herrero.
Ther Adv Med Oncol, 2021 Feb 23; 13. PMID: 33613695    Free PMC article.
Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.
Shiwei Liu, Shiyan Zeng, +7 authors, Purong Zhang.
Breast Cancer Res Treat, 2020 Nov 10; 185(3). PMID: 33165709
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Otto Metzger Filho, Daniel G Stover, +19 authors, W Fraser Symmans.
JAMA Oncol, 2021 Feb 19; 7(4). PMID: 33599688    Free PMC article.
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Yuan, Jin Sun Lee, +19 authors, Joanne Mortimer.
Oncologist, 2020 Oct 25; 26(3). PMID: 33098195    Free PMC article.
Identification of genes that correlate clear cell renal cell carcinoma and obesity and exhibit potential prognostic value.
Jiale Zhou, Zhaolin Yang, +3 authors, Yonghui Chen.
Transl Androl Urol, 2021 Mar 16; 10(2). PMID: 33718070    Free PMC article.
Regressed Seminoma with Metastases to the Jejunum and Retroperitoneum.
Nozomi Kashu, Shoji Oura, Naoki Kataoka, Shinichiro Makimoto.
Case Rep Oncol, 2021 Mar 30; 14(1). PMID: 33776737    Free PMC article.
Tumor-infiltrating lymphocytes in the immunotherapy era.
Sterre T Paijens, Annegé Vledder, Marco de Bruyn, Hans W Nijman.
Cell Mol Immunol, 2020 Nov 04; 18(4). PMID: 33139907    Free PMC article.
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer.
G Griguolo, G Serna, +22 authors, P Nuciforo.
NPJ Precis Oncol, 2021 Mar 21; 5(1). PMID: 33742063    Free PMC article.
Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
M F Tolba, H Elghazaly, +2 authors, S M Tolaney.
Clin Transl Oncol, 2021 Apr 20; 23(10). PMID: 33871826
Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.
Enora Laas, Julie Labrosse, +9 authors, Fabien Reyal.
Br J Cancer, 2021 Feb 10; 124(8). PMID: 33558711    Free PMC article.
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Francesca Ligorio, Giovanni Fucà, +9 authors, Claudio Vernieri.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33921727    Free PMC article.
Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis.
Sara E Nunnery, Ingrid A Mayer, Justin M Balko.
Cancer J, 2021 Jan 22; 27(1). PMID: 33475287    Free PMC article.
Genomic features of rapid versus late relapse in triple negative breast cancer.
Yiqing Zhang, Sarah Asad, +28 authors, Daniel G Stover.
BMC Cancer, 2021 May 20; 21(1). PMID: 34006255    Free PMC article.
The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
Lijiang He, Hainan Yang, Jingshan Huang.
BMC Cancer, 2021 May 22; 21(1). PMID: 34016089    Free PMC article.
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.
Ilana Schlam, Sandra M Swain.
NPJ Breast Cancer, 2021 May 22; 7(1). PMID: 34016991    Free PMC article.
The low expression of NUP62CL indicates good prognosis and high level of immune infiltration in lung adenocarcinoma.
Shiqi Ren, Wei Wang, +6 authors, Lanlan Yao.
Cancer Med, 2021 May 03; 10(10). PMID: 33934535    Free PMC article.
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
Monika Graeser, Friedrich Feuerhake, +19 authors, Nadia Harbeck.
J Immunother Cancer, 2021 May 09; 9(5). PMID: 33963012    Free PMC article.
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer.
Koji Takada, Shinichiro Kashiwagi, +9 authors, Masaichi Ohira.
BMC Womens Health, 2021 May 31; 21(1). PMID: 34051785    Free PMC article.
CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM).
Anja Kathrin Wege, Tobias F Dreyer, +3 authors, Holger Bronger.
Cancers (Basel), 2021 Jun 03; 13(10). PMID: 34070094    Free PMC article.
Development of Immunotherapy Combination Strategies in Cancer.
Timothy A Yap, Eileen E Parkes, +3 authors, Hussein A Tawbi.
Cancer Discov, 2021 Apr 04; 11(6). PMID: 33811048    Free PMC article.
Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model.
Sanambar Sadighi, Ramezanali Sharifian, +4 authors, Samad Muhammadnejad.
Iran J Basic Med Sci, 2021 Jun 08; 24(4). PMID: 34094037    Free PMC article.
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.
François Bertucci, Laurys Boudin, +9 authors, Emilie Mamessier.
Oncoimmunology, 2021 Jun 10; 10(1). PMID: 34104544    Free PMC article.
HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tamera J Lillemoe, Mara Rendi, +7 authors, Karen K Swenson.
Int J Breast Cancer, 2021 Jun 15; 2021. PMID: 34123431    Free PMC article.
Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
Quentin Klopfenstein, Valentin Derangère, +5 authors, Sylvain Ladoire.
J Immunother Cancer, 2021 Jun 05; 9(6). PMID: 34083415    Free PMC article.
Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.
Mieke R Van Bockstal, Aline François, +39 authors, Christine Galant.
Mod Pathol, 2021 Jul 05;. PMID: 34218258
Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer.
Miquel Ensenyat-Mendez, Pere Llinàs-Arias, +5 authors, Diego M Marzese.
Front Oncol, 2021 Jul 06; 11. PMID: 34221999    Free PMC article.
Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
Edoardo Isnaldi, Domenico Ferraioli, +6 authors, Gabriele Zoppoli.
Breast Cancer Res Treat, 2019 Jun 22; 177(2). PMID: 31222709
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.
Natalia Palazón-Carrión, Carlos Jiménez-Cortegana, +9 authors, Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA).
Sci Rep, 2021 Jul 15; 11(1). PMID: 34257359    Free PMC article.
FOXA1 overexpression suppresses interferon signaling and immune response in cancer.
Yundong He, Liguo Wang, +26 authors, Haojie Huang.
J Clin Invest, 2021 Jun 09; 131(14). PMID: 34101624    Free PMC article.
Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone.
Jason A Mouabbi, Momal Chand, +7 authors, Valentina Hoyos.
Cancer Med, 2021 Jun 04; 10(14). PMID: 34080777    Free PMC article.
Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.
Jia Wu, Aaron T Mayer, Ruijiang Li.
Semin Cancer Biol, 2020 Dec 09;. PMID: 33290844    Free PMC article.
Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy.
Lun Li, Min Chen, +7 authors, Jiong Wu.
Front Oncol, 2021 Aug 03; 11. PMID: 34336634    Free PMC article.
The Clinical Value of VDR and CTLA 4 in Evaluating the Prognosis of Invasive Duct Carcinoma of Egyptian Patients and their Benefit as a Target Therapy.
Nanis Shawky Holah.
Asian Pac J Cancer Prev, 2021 Apr 29; 22(4). PMID: 33906311    Free PMC article.
Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.
Masanori Oshi, Tsutomu Kawaguchi, +15 authors, Kazuaki Takabe.
Am J Cancer Res, 2021 Aug 07; 11(7). PMID: 34354864    Free PMC article.
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions.
Fokhrul Hossain, Samarpan Majumder, Justin David, Lucio Miele.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359640    Free PMC article.
Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomarker and a Potential Therapeutic Strategy in Breast Cancer.
Diana P Saraiva, Sofia Azeredo-Lopes, +9 authors, M Guadalupe Cabral.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359741    Free PMC article.
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
Antonino Grassadonia, Vincenzo Graziano, +10 authors, Nicola Tinari.
Cells, 2021 Aug 08; 10(7). PMID: 34359855    Free PMC article.
Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
Nanna Jørgensen, Thomas Vauvert F Hviid, +8 authors, Anne-Vibeke Lænkholm.
Br J Cancer, 2021 Aug 09;. PMID: 34365471
Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment.
Guoshuang Shen, Fuxing Zhao, +4 authors, Jiuda Zhao.
Front Oncol, 2021 Aug 10; 11. PMID: 34367947    Free PMC article.
Systematic Review.
Dissecting the biological heterogeneity of HER2-positive breast cancer.
Francesco Schettini, Aleix Prat.
Breast, 2021 Aug 16; 59. PMID: 34392185    Free PMC article.
Physalin A, 13,14-Seco-16, 24-Cyclo-Steroid, Inhibits Stemness of Breast Cancer Cells by Regulation of Hedgehog Signaling Pathway and Yes-Associated Protein 1 (YAP1).
Yu-Chan Ko, Hack Sun Choi, Ren Liu, Dong-Sun Lee.
Int J Mol Sci, 2021 Aug 28; 22(16). PMID: 34445421    Free PMC article.
Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer.
Darren Kilmartin, Mark O'Loughlin, +25 authors, Grace Callagy.
Cancers (Basel), 2021 Sep 11; 13(17). PMID: 34503219    Free PMC article.
Heparanase is a novel biomarker for immune infiltration and prognosis in breast cancer.
Wen-Jing Yang, Lin Shi, Xiao-Min Wang, Guo-Wang Yang.
Aging (Albany NY), 2021 Aug 31; 13(16). PMID: 34461608    Free PMC article.
Nuclear Aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer.
Shulan Sun, Wei Zhou, +8 authors, Haozhe Piao.
Cancer Commun (Lond), 2021 Jul 13; 41(9). PMID: 34251762    Free PMC article.
Research progress on CD169-positive macrophages in tumors.
Xianming Hou, Ge Chen, Yupei Zhao.
Am J Transl Res, 2021 Sep 21; 13(8). PMID: 34539981    Free PMC article.
Immunity and Breast Cancer: Focus on Eosinophils.
Aurélie Poncin, Concetta Elisa Onesti, +4 authors, Guy Jerusalem.
Biomedicines, 2021 Sep 29; 9(9). PMID: 34572273    Free PMC article.
Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial.
Si-Yuan Zhu, Ding Ma, Zhi-Ming Shao, Ke-Da Yu.
Front Mol Biosci, 2021 Oct 09; 8. PMID: 34621789    Free PMC article.
Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy.
Wenxiang Zhang, Xiangyi Kong, +6 authors, Jing Wang.
Front Oncol, 2021 Oct 12; 11. PMID: 34631507    Free PMC article.
Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
Curtis A Clark, Eddy S Yang.
Front Oncol, 2021 Oct 12; 11. PMID: 34631532    Free PMC article.
Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment.
Xueying Wang, Kui Cao, +10 authors, Susheng Miao.
Cancer Immunol Immunother, 2021 Oct 14;. PMID: 34643766
Immunomodulating Therapies in Breast Cancer-From Prognosis to Clinical Practice.
Marcus Schmidt, Anne-Sophie Heimes.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638367    Free PMC article.
Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?
Ornella Franzese, Francesco Torino, +8 authors, Enzo Bonmassar.
Int J Mol Sci, 2021 Oct 14; 22(19). PMID: 34639014    Free PMC article.
Prognostic impact of tertiary lymphoid structures in breast cancer prognosis: a systematic review and meta-analysis.
Na-Na Zhang, Feng-Jin Qu, +5 authors, Yi Lv.
Cancer Cell Int, 2021 Oct 17; 21(1). PMID: 34654433    Free PMC article.
Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.
Koji Takada, Shinichiro Kashiwagi, +7 authors, Masaichi Ohira.
BMC Cancer, 2021 Oct 22; 21(1). PMID: 34670511    Free PMC article.
Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer.
Chikako Honda, Sasagu Kurozumi, +11 authors, Takaaki Fujii.
Mol Clin Oncol, 2021 Oct 22; 15(6). PMID: 34671471    Free PMC article.
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer.
Won-Ji Ryu, Joo Hyuk Sohn.
Pharmaceuticals (Basel), 2021 Oct 24; 14(10). PMID: 34681231    Free PMC article.
Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.
Asumi Sakaguchi, Yoshiya Horimoto, +9 authors, Shigehisa Kitano.
Breast Cancer Res, 2021 Oct 31; 23(1). PMID: 34715905    Free PMC article.
Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy.
Anne-Sophie Heimes, Hannah Krämer, +6 authors, Marcus Schmidt.
Breast Care (Basel), 2021 Nov 02; 16(5). PMID: 34720803    Free PMC article.
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.
Brian D Lehmann, Antonio Colaprico, +12 authors, X Steven Chen.
Nat Commun, 2021 Nov 03; 12(1). PMID: 34725325
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
Katherine E Hutchinson, Susan E Yost, +8 authors, Yuan Yuan.
Clin Cancer Res, 2019 Oct 16; 26(3). PMID: 31611282    Free PMC article.